Hi Maneka,
Our approach in Ontario is similar to what Lori described. Now that the MENTOR trial has been published and shows superiority of rituximab over cyclosporine in terms of proteinuria remission/relapse, we have been adding this as an argument in our letters to insurers. Since the trial is so new, I do not yet know how the funders are responding to this.
Clara
Glomerulonephritis Clinic
London Health Sciences Centre
